Drug
Beruzatatug pelitecan clinical trials
Also written YL202 and BNT326.
- studies test it
- 9
- open now
- 8
- in phase 3
- 2
- first study started
- 2022
Keep track of what changes. Save the beruzatatug pelitecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 6
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
MediLink Therapeutics (Suzhou) Co., Ltd. (7) · BioNTech SE (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses beruzatatug pelitecan is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2BioNTech SENCT07111520Written as BNT326
- A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCRecruitingPhase 2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06439771Written as YL202 should be intravenously infused
- A Study of YL202 in Patients With Advanced Solid TumorsRecruitingPhase 2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07202364Written as YL202
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsRecruitingPhase 1/2BioNTech SENCT07070232Written as BNT326
- Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07416994Written as YL202
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454Written as YL202
- A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingPhase 2MediLink Therapeutics (Suzhou) Co., Ltd.NCT06107686Written as YL202 should be intravenously infused
- A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2MediLink Therapeutics (Suzhou) Co., Ltd.NCT07169994Written as YL202 for injection; Toripalimab injection
- A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast CancerActive, not recruitingPhase 1MediLink Therapeutics (Suzhou) Co., Ltd.NCT05653752Written as YL202
Codes
What other systems call beruzatatug pelitecan · ClinicalTrials.gg INT016318
- UNII (FDA) DAW7F54AQEBERUZATATUG PELITECANOne source FDA
- NCI Thesaurus C199281Beruzatatug PelitecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DAW7F54AQE | BERUZATATUG PELITECAN | One source FDA |
| NCI Thesaurus | C199281 | Beruzatatug Pelitecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.